Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma
- 7 March 2012
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 76 (4), 586-592
- https://doi.org/10.1111/j.1365-2265.2011.04272.x
Abstract
To assess (i) the influence of Thyrotropin (TSH) suppression at a level of 0·1 mU/l, are associated with an impaired prognosis. There is, however, no prognostic benefit from suppressing TSH to levels lower than 0·1 mU/l. On the contrary, an improvement in prognosis might be achieved by keeping FT3 levels as low as possible.Keywords
This publication has 24 references indexed in Scilit:
- Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasionEndocrine-Related Cancer, 2010
- Thyroid receptor: roles in cancerTrends in Endocrinology & Metabolism, 2009
- Effects of thyroid hormones on human breast cancer cell proliferationThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-Cell translocation gene 2The Prostate, 2008
- Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer PatientsJournal of Clinical Endocrinology & Metabolism, 2007
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Letter to the EditorsClinical Endocrinology, 1997
- Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assaysJournal of Clinical Endocrinology & Metabolism, 1993
- TRIAC (3,5,3′‐triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with l‐thyroxineClinical Endocrinology, 1991